ADVERTISEMENT
Women and Black Patients Less Likely to Receive Catheter-Based Treatment for Pulmonary Embolism
Data from REAL-PE analysis demonstrated only 0.5% of all PE patients received catheter-based therapy
Data from REAL-PE analysis demonstrated only 0.5% of all PE patients received catheter-based therapy
Long Beach, Calif. – New data from the REAL-PE analysis investigated catheter-based pulmonary embolism (PE) treatment, showing women and Black people were less frequently treated with minimally invasive therapy compared to men or non-Black patients. The late-breaking results were presented May 3rd at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
PE is often caused by blood clots in the legs, otherwise known as deep vein thrombosis, that travel through the veins and into the lungs. PE affects around 900,000 people in the U.S. each year, with 10-30% dying within one month of diagnosis. Ultrasound-assisted catheter-directed thrombolysis (USCDT), a common invasive treatment option for PE, enables deeper penetration of the clot-busting medication into the clot, restoring normal blood flow faster. Mechanical thrombectomy (MT), another invasive treatment method has been shown to reduce thrombus burden and pulmonary artery pressure (PAP) and to improve right ventricular (RV) function in patients with high-risk or intermediate-high-risk PE.
REAL-PE analyzed data from patients within the Truveta database diagnosed with PE and treated with USCDT or MT for PE. Patient characteristics including race, ethnicity, age, sex, comorbidities, and prior diagnoses were assessed to investigate their association with the type of treatment used. Of the more than 430,000 patients diagnosed with PE, about 2,000 patients analyzed were treated with one of the invasive therapies. Women or Black patients were less frequently treated with invasive therapy than men or non-Black patients. Moreover, women more than men and white people more than Black people had higher bleeding rates.
“Although this data demonstrates the value of real-world data in the assessments of new technologies in which randomized data are not always available, there is still work that needs to be done to evaluate the current utilization of advanced therapies for PE in underrepresented patient populations,” said Sahil A. Parikh, MD, Associate Professor of Medicine, Columbia University Irving Medical Center, and lead author of the study. “Evaluating care disparities in real clinical practices is key to addressing the existing barrier and improving patient outcomes.”
Session Details:
- “Disparities in Pulmonary Embolism Care: Insights from Big Data Analytics”
- Friday, May 3, 2024; 2:02-2:09 PM PT
- Long Beach Convention Center, 104A, First Level
###
About Society for Cardiovascular Angiography & Interventions (SCAI)
The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 4,500 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease. For more information, visit https://scai.org/.
For more information about the SCAI 2024 Scientific Sessions, visit https://scai.org/scai-2024-scientific-sessions. Follow @SCAI on X (formerly Twitter) and on LinkedIn for the latest heart health news and use #SCAI2024 to follow the latest discussions.
Find More:
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
Podcasts: Cath Lab Conversations
Go to Cath Lab Digest's current issue page
